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Case report
Sivelestat relieves respiratory distress
refractory to dexamethasone in all-trans
retinoic acid syndrome: a report of two cases
All-trans retinoic acid (ATRA) treatment improves
the overall survival of patients with acute promyel-
ocytic leukemia (APL) by reducing early deaths
because of bleeding events and sepsis (1), but some
patients receiving ATRA develop respiratory dis-
tress associated with pulmonary inﬁltration, con-
solidation, and ground-glass opacities on chest
radiographs. This condition is known as ATRA
syndrome (1, 2). To manage these symptoms,
steroids and cytoreduction chemotherapy are
administered based on the patient’s leukocyte count
(1, 2). Some patients, however, require prolonged
mechanical ventilation (2) and occasionally ATRA
syndrome can be fatal (3).
We describe two APL patients who were treated
with ATRA and then suﬀered from respiratory
distress that was not improved by standard agents.
However, ﬁndings on chest radiographs and venti-
lation parameters improved following additional
administration of Sivelestat, a small molecule
inhibitor of neutrophil elastase.
Case 1
A 16-yr-old left-handed girl was admitted to our
hospital because of menorrhagia and pancytopenia.
The patient had been well a month earlier, when she
had experienced a prolonged period and heavy
menstrual ﬂow. She consulted a clinic because of
general fatigue, and was referred to this hospital.
She had a temperature of 37.5C, a pulse rate of
110/min, a respiration rate of 40/min, and her
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Abstract: Treatment with all-trans retinoic acid (ATRA) improves the
prognosis of patients with acute promyelocytic leukemia (APL), but
ATRA syndrome may occur as a possible fatal side eﬀect, especially in
cases refractory to medication or involving pulmonary hemorrhage. We
describe two patients with APL who suﬀered from intracranial hemor-
rhage. The ﬁrst patient was a 16-yr-old girl who was treated with ATRA
and then developed respiratory distress refractory to treatment with
dexamethasone combined with anthracycline-cytarabine cytoreduction
therapy. Treatment with Sivelestat, a small molecule inhibitor of neu-
trophil elastase, achieved rapid improvement in oxygenation and chest
radiograph ﬁndings, and the patient has been in complete remission for
24 months. The second patient was a 10-yr-old boy in whom pulmonary
hemorrhage developed following administration of ATRA, dexameth-
asone and cytoreduction therapy. Aspiration and administration of
Sivelestat improved oxygenation and he remained stable. Hematological
improvement was also achieved, but the patient died of brain dysfunc-
tion because of cerebral edema accompanied by intracranial bleeding.
The two cases suggest that Sivelestat may be eﬀective as an additional
agent in the treatment of refractory ATRA syndrome, and, therefore,
prospective randomized studies of treatment protocols are warranted.
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448blood pressure was 130/80 mmHg. The liver and
spleen were palpable at 3 cm subcostally. No
lymphadenopathy was found. Her white blood cell
count (WBC) was 900 cells/lL, with 4% neu-
trophils, 81% lymphocytes, 1% monocytes, and
14% abnormal cells that contained folded nuclei,
some granules and Auer rods. Her hemoglobin
level was 4.7 g/dL, and her platelet count was
27 000 cells/lL. Prothrombin time (PT) and acti-
vated partial thromboplastin time (APTT) were
15.1 and 33.4 s, respectively, and the ﬁbrinogen
level was 71 mg/dL. Following diagnosis of acute
myelogenous leukemia of subtype M3, ATRA was
administered orally and gabexate mesilate (GM)
intravenously. Two packs of erythrocytes were
transfused.
The next morning the patient vomited and
became drowsy, and a seizure accompanied by
right hemiparesis developed. A CT scan of the head
disclosed a left subcortical hematoma (Fig. 1A) and
minor bleeding in the right pons. A hematectomy
was performed, after which administration of
ATRA was continued under mechanical ventila-
tion. On hospital day 5, her WBC count increased
to 15 000 cells/lL, at which time ATRA was
discontinued, and administration of dexametha-
sone, daunorubicin, and cytarabine was initiated
intravenously. Oxygen saturation decreased to 90%
despite 60% oxygen being supplied, so FiO2 was
increased to 1.0. A chest radiograph revealed an
enlarged heart and bilateral diﬀuse ground-glass
opacity (Fig. 1B). Another chest radiograph on the
following day showed extensive consolidation
(Fig. 1C). Her WBC count, however, decreased to
3700 cells/lL. After obtaining informed consent,
Sivelestat was administered because oxygen satura-
tion had decreased to 78% despite positive end-
expiratory pressure (PEEP) being increased to
15 mm H2O and peak inspiratory pressure to
25 mm H2O. The next morning, PaO2 had im-
proved to 278 mmHg, and a third chest radiograph
revealed improvement of consolidation (Fig. 1D).
Subsequently, FiO2, PEEP and peak inspiratory
pressure were decreased gradually and mechanical
ventilation was discontinued on hospital day 10.
Sivelestat and dexamethasone were discontinued on
day 12, and complete remission was achieved on
day 35. The patient received 5 cycles of consolid-
ation chemotherapy containing ATRA, and ATRA
syndrome did not recur. The patient has now been
in complete remission for 24 months.
Case 2
A 10-yr-old boy who had previously been healthy
was admitted to our hospital with diarrhea and
epistaxis. He presented to the emergency outpatient
unit of the hospital with watery diarrhea. His father
reported that the patient had suﬀered from repea-
ted nasal bleeding and some eruptions had been
noticed on his abdomen a few days earlier. The
patient was a Brazilian of Japanese ancestry who
had immigrated to Japan 6 months earlier.
Patient ﬁndings were as follows; temperature
37.4C, pulse 92/min, respiration 22/min, and
blood pressure 110/62 mmHg. Physical examina-
tion disclosed petechiae on the neck and abdomen.
No lymphadenopathy or hepatosplenomegaly was
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Fig. 1. (A) A cranial CT-scan showing
a high intensity lesion of 7 cm in
diameter in the left subcortical region.
(B–D) Serial chest radiographs show-
ing progression and resolution of pul-
monary inﬁltrates. (B) Five days after
ATRA treatment, a chest radiograph
showed bilateral diﬀuse ground-glass
opacity, which was prominent in the
right-middle to lower lung ﬁelds, and
an enlarged cardiac silhouette. (C)
Despite withdrawal of ATRA and
administration of dexamethasone,
daunorubicin and cytarabine, another
radiograph on hospital day 6 revealed
extensive consolidation. (D) After
administration of Silvelestat, the con-
solidation had almost disappeared on
the following morning.
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449found. His WBC count was 41 000 cells/lL, with
3% neutrophils, 7% lymphocytes, 0.5% mono-
cytes, and 85% abnormal cells with bilobal and
reniform nuclei and agranular cytoplasms. His
hemoglobin level was 10.6 g/dL, his platelet count
was 35 000 cells/lL, PT was 17.3 s, APTT was
25.4 s, the ﬁbrinogen level was 50 mg/dL, and the
concentration of ﬁbrinogen degradation products
was 26.6 lg/mL. The patient was given a platelet
transfusion and treated with GM and fresh frozen
plasma. On hospital day 4, a central venous
catheter was introduced under anesthesia, and
the patient subsequently became agitated and
vomited. A chest radiograph taken at this time
showed inﬁltration in the upper right lung ﬁeld
(Fig. 2A).
On hospital day 7, a diagnosis of M3 variant
APL was made, based on a RT-PCR analysis that
showed a PML-RAR gene rearrangement. His
WBC count was 116 000/lL. ATRA was com-
menced orally and cytarabine and daunorubicin
were administered intravenously. Then, however,
the patient vomited bloody specimens and became
drowsy. A CT scan of the head revealed multiple
sites of intraparenchymal bleeding and diﬀuse
cerebral swelling, which was particularly prominent
in the pons (Fig. 2B). Dexamethasone and mann-
itol were administered intravenously. Because SpO2
decreased to 80% with a 60% O2 supply, the
patient was intubated and placed under mechanical
ventilation. A bloody specimen was suctioned from
the tracheal tube. Coﬀee-colored contents were also
drained from an orogastric tube. Therefore, cimet-
idine was administered intravenously. Platelets and
erythrocytes were transfused.
The next day, the bilateral pupils were enlarged
and corneal reﬂexes were absent. Another CT scan
of the head revealed deterioration of brain edema,
and a chest radiograph on hospital day 9 disclosed
new consolidations in the bilateral lower lung ﬁelds
(Fig. 2C). Aspirated matter suctioned from an
endotracheal tube became bloodier despite repeated
transfusion of platelets and fresh frozen plasma.
Administration of Sivelestat was commenced after
obtaining informed consent from his parents, and
the following day SpO2 suddenly fell to 80%.
However, after suctioning with a tracheal endo-
scope, it increased to 95%. A chest radiograph on
the following day showed reduced pulmonary
inﬁltrates (Fig. 2D), and oxygenation remained
stable without suctioning. However, blood ﬂow in
the carotid arteries could not be detected on a
transcranial Doppler echogram, and his corneal
reﬂexes remained absent on day 10. Electroen-
cephalogram waves and auditory brainstem re-
sponses were ﬂattened. Although a blood
examination revealed a leukocyte count that had
decreased to 4500/lL and coagulopathy was trea-
ted acceptably, the patient deteriorated further and
died of brain dysfunction on day 13.
Discussion
Acute respiratory distress syndrome and acute lung
injury (ARDS/ALI) is a critical illness syndrome
consisting of acute impaired oxygenation and
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Fig. 2. (A) A radiograph of the chest
taken during recovery from general
anesthesia, showing hazy perihilar and
right upper zone opacities. (B) ATRA,
dexamethasone, daunorubicin and
cytarabine were administered on hos-
pital day 7, and the patient then be-
came drowsy. A computed
tomography scan of the head disclosed
multiple high intensity lesions of vary-
ing sizes in the brain parenchyma. (C)
On hospital day 9, another radiograph
showed new consolidations in the
bilateral lower lung ﬁelds. (D) After
administration of Silvelestat and suc-
tioning of a bloody specimen using a
bronchoscope, the consolidation
diminished in thickness and oxygen-
ation remained stable without suc-
tioning.
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450bilateral pulmonary inﬁltrates without left atrial
hypertension, and arises from a variety of underly-
ing insults (4). The clinical features of ARDS/ALI,
rapid onset of respiratory failure in patients with
risk factors, occasionally accompanied by involve-
ment of other organs (4), are similar to those of
ATRA syndrome (2, 3). In addition, several aspects
of the radiologic manifestations of the two syn-
dromes resemble each other, and include bilateral
inﬁltration and pleural eﬀusion (5). Case 1 was
diagnosed as ATRA syndrome based on her clinical
course, despite the development of intracranial
hemorrhage. In case 2, the patient suﬀered from
aspiration pneumonia, intracranial bleeding and
pulmonary hemorrhage, making a diagnosis of
ARDS/ALI possible. However, because diﬀuse
alveolar hemorrhage in ATRA syndrome (6, 7)
and rapid progression of ATRA syndrome in M3
variant APL (8) have been reported, the secondary
pulmonary bleeding in case 2 might have been
because of ATRA syndrome.
Neutrophil elastase is an enzyme that causes
endothelial damage and increases permeability in
ARDS/ALI (9). Sivelestat is a neutrophil elastase
inhibitor that has been shown to be eﬀective in
animal models of ARDS/ALI. However, the eﬃc-
acy of Sivelestat for ALI patients remains contro-
versial: a Japanese phase III study reported good
results (10), but Zeiher et al. found that Sivelestat
combined with low tidal volume ventilation had no
eﬀect on 28-d all-cause mortality or ventilator-free
days (11). Despite this uncertainty, we decided to
use Sivelestat because our two patients were in
serious respiratory distress that appeared to be
refractory to other agents. From a safety perspec-
tive, double-blind placebo-controlled trials of
ARDS/ALI have shown no diﬀerence in adverse
events between Sivelestat-treated and control
groups (10, 11). Respiratory functions and abnor-
malities on chest radiographs improved quickly
after administration of Sivelestat in case 1.
Nicolls et al. (6) reported a case of ATRA
syndrome with diﬀuse alveolar hemorrhage, in
whom a lung biopsy revealed pulmonary capillari-
tis; i.e., inﬁltration of numerous neutrophils into
the lung parenchyma. Since neutrophil elastase
released from diﬀerentiated APL cells that have
inﬁltrated the lung capillaries may be the main
cause of damage to endothelial cells, the rapid
improvement in respiratory function yielded by
Sivelestat treatment may be because of its inhibi-
tory eﬀect on the enzyme. Pulmonary hemorrhage
is another serious and potentially fatal condition
that may not always be treatable with steroids and
cytoreduction agents (6, 7), and prevention of lung
hemorrhage by Sivelestat has been described in a
rat model of cerulean-induced pancreatitis (12). In
case 2, it is of interest that pulmonary bleeding
refractory to transfusions of platelets and fresh
frozen plasma was well controlled by introducing
Sivelestat.
Intracranial hemorrhage is another life-threaten-
ing complication. Although coagulation disorders
coexist frequently in APL, no signiﬁcant diﬀerences
in the incidence of early hemorrhagic death
between subgroups administered heparin, anti-
ﬁbrinolytics and supportive therapy alone were
reported in a large retrospective study (13). GM, a
protease inhibitor, is used for coagulation disorders
in Japan. The eﬃcacy of GM for disseminated
intravascular coagulation accompanying malignant
neoplasms was described in preliminary report (14).
Prospective studies of this agent are also warranted
because reducing early death because of hemor-
rhage remains challenging.
In conclusion, we have reported on two patients
with APL who suﬀered from intracranial hemor-
rhage and developed severe respiratory distress,
with or without pulmonary hemorrhage. The res-
piratory condition was refractory to dexametha-
sone and anthracycline-cytarabine antineoplastic
therapy, but Sivelestat achieved improvement in
oxygenation and chest radiograph ﬁndings. There-
fore, our results suggest that prospective studies are
warranted to conﬁrm the safety and eﬃcacy of
Sivelestat in the treatment of severe respiratory
distress.
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